A preliminary analysis based on high-resolution metabolomics pointed to three blood plasma metabolites with apparent ties to active, pulmonary tuberculosis.
The tool allows users to search for unexpected modifications and other phenomena that are difficult to identify using conventional mass spec search software.
A team from the EPFL has identified the chemical NTCB as a potential digestion reagent for middle-down work, though bioinformatic hurdles still remain.
The agreement is part of a larger effort by the company to apply its Signabody affinity reagents to toxicity biomarker work and other areas of drug development.
Based on multiplexed ion beam imaging, the system, which the company plans to launch next year, will compete most directly with Fluidigm's Hyperion platform.
According to the company, its approach allows for improved detection of EV-bound proteins and phosphoproteins, which it is using for biomarker discovery.
After an unsuccessful commercialization attempt more than a decade ago, the company is bringing a revamped version of the ion mobility technology to market.
According to the researchers, this is one of the first successful such predictions and could aid the understanding of links between gene expression and metabolism.
PNNL researchers have developed a targeted mass spec approach that they said could enable single-cell measurement of the 2,500 most abundant human proteins.
A workflow developed by the company along with Max Planck researchers demonstrates the system's potential for enabling high-throughput proteomic experiments.
The method combines stable isotope dimethyl labeling with DiLeu isobaric tagging and allows multiplexing of up to 24 samples in a single mass spec experiment.
The ability to effectively use FFPE tissue opens up a large number of clinical samples for analysis, many with quality data on patient demographics, treatment, and outcomes.
The company said the funds will be used to expand its management team and complete commercialization of its mass spec multinozzle emitter array technology.
The company reported revenues of $443.7 million and organic growth of 3 percent, driven in large part by strength in its scientific instruments business.
The University of Zurich's Ruedi Aebersold and his colleagues analyzed a dozen HeLa cell lines to find differences in gene expression, protein levels, and more.
